Professor Keith Wheatley BA, DPhil

Professor Keith Wheatley

Institute of Cancer and Genomic Sciences
Professor of Clinical Trials

Contact details

Telephone
+44 (0)121 415 9119
Fax
+44 (0)121 414 3700
Email
k.wheatley@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Professor of Clinical Trials, specialising in management (design, monitoring, analysis and reporting) of clinical trials in a range of disease areas, mainly paediatric oncology and also leukaemia and skin cancer, along with related meta-analyses and add-on biomarker studies.

Qualifications

  • Diploma in Applied Statistics, University of Oxford 1987
  • DPhil (Ethology), University of Sussex 1984
  • University of Sussex: doctoral studies in Biology Department on the “Organisation of Song in the Mistle Thrush” 1984
  • BA Cantab II, Natural Sciences - 1979

Biography

Professor Keith Wheatley is Professor of Clinical Trials in the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.  

He spent 13 years at the Clinical Trial Service Unit (CTSU) in Oxford before moving to the Birmingham Clinical Trials Unit (BCTU) in 1998 and then to CRCTU in 2009.  His main responsibilities are the design, management, analysis and reporting of large randomised trials in the academic setting, though earlier Phase trials are becoming an increasing part of his work.  Systematic reviews, especially meta-analyses of randomised trials, and add-on biomarker studies are a further major interest.  

Current disease areas in which trials, systematic reviews and biomarker studies are underway include paediatric oncology, acute myeloid leukaemia and skin cancer.  

Teaching

  • MSc in Clinical Oncology, University of Birmingham
  • Small group teaching for undergraduate medical students, University of Birmingham
  • Supervision of student projects in intercalated BMedSc, University of Birmingham
  • Research methods for clinical trials, University of Birmingham

Research

Children’s cancer trials include:

  • EE2012 (trial in newly diagnosed Ewing’s sarcoma)
  • rEECur (Ewing’s sarcoma trial in relapsed patients)
  • BEACON (trial in relapsed neuroblastoma)
  • IMAT (trial of radiotherapy in neuroblastoma)
  • LUDO (trial of radiotherapy in neuoblastoma)
  • MyeCHILD (trial for paediatric AML)
  • PEP-talk2 (supportive care trial of varicella prophylaxis)
  • VIT (trial in relapsed soft tissue sarcoma)
  • Ependymoma II (trial of treatments for ependymoma)
  • Inter-B-NHL 2010 (trial in non-Hodgkin’s lymphoma)
  • PHITT (trial in liver cancer)
  • PARC (Phase I/II trial of BCT-100)
  • SIOP-E HRMB (trial in high-risk medulloblastoma)

Skin cancer trials include:

  • LM1 (Phase II trial of imiquimod for lentigo maligna)
  • SPOT (feasibility study of treatment to prevent squamous cell carcinoma)
  • UKMCC-1 (Phase II trial of pazopanib for Merkel cell carcinoma)

Haematological malignancy:

  • FIGARO
  • RAvVA
  • BaP (Trial of non-intensive therapy for elderly/unfit patients with leukaemia

Systematic reviews and meta-analysis: disease areas include AML, neuroblastoma, melanoma, brain tumours, renal cancer, Ewing’s sarcoma, soft tissue sarcoma.

Non-cancer trials include:

  • PD MED (medical treatments for Parkinson’s disease)
  • PD SURG (deep brain stimulation for Parkinson’s disease)
  • PD REHAB (physiotherapy and occupational therapy for Parkinson’s disease)
  • PD COMM (speech and language therapy for patients with Parkinson’s disease)
  • ASTRAL (Angioplasty and/or Stent for Renal Artery Lesions):
  • PEXIVAS (International trial for patients with anca-associated vasculitis)
  • PREDNOS (steroids for paediatric nephrotic syndrome)
  • OTCH (Trial of exercise for stroke patients in nursing homes)

Other activities

Committee/Group Membership: (past and present)

  • NICE Interventional Procedures Advisory Committee (IPAC)
  • NIHR HTA Clinical Evaluation and Trials (CET) Board
  • NCRI Melanoma Clinical Studies Group
  • NCRI Haematological Oncology Clinical Studies Group
  • NCRI Children’s Cancer and Leukaemia Clinical Studies Group
  • NCRI Biomarkers and Imaging Clinical Studies Group
  • DeNDRoN Parkinson’s Disease Clinical Studies Group
  • MRC Biostatistics Fellowship Panel (also Population Health Scientist and Methodology Research)
  • Clinical Trials Committee of the Renal Association (ex)
  • Kidney Research UK Research Grants Committee
  • NCRI Haematological Oncology CSG AML, MDS (myelodysplastic syndromes) and MPN (myeloproliferative disorders) Subgroups
  • NCRI Sarcoma CSG Bone Sarcoma Subgroup
  • NCRI Lymphoma CSG Paediatric NHL Subgroup
  • Cochrane Haematological Malignancies Group (Methods Editor)
  • Clinical Trials Subgroup of the UK Myeloma Forum
  • UK Scientific Advisory Panel of the International Myeloma Foundation
  • Welcome Trust Clinical Research Facility (Birmingham) – Scientific Advisory Committee
  • Myeloma UK Research Programme Peer Review Panel
  • Birmingham Centre for Clinical Trials (BCCT) Executive
  • Leukaemia Research Clinical Trials Advisory Panel (CTAP) (ex)
  • Clinical Trials Committee of the Renal Association (ex)
  • Children’s Cancer and Leukaemia Group (CCLG) Clinical Trial Review Group (CTRG) (ex)

Data Monitoring Committees

  • National Blood Service Clinical Studies Unit: several trials in progress.
  • ESPRIT: International trial of anticoagulation to prevent stroke in patients with reversible ischaemia.
  • RE04: MRC trial of interferon, interleukin-2 and 5-FU for renal cancer.
  • Hydra: Trial of chemotherapy for renal cancer.
  • VITATOPS: International trial of vitamins for stroke patients.
  • Membranous nephropathy: MRC trial of prednisolone + clorambucil v. cyclosporin v. supportive care only.
  • DiGEM: Patient self-monitoring of blood glucose levels in diabetics.
  • SPIRIT: Trial of imatinib and interferon for chronic myeloid leukaemia.
  • SPIRIT2: Trial of imatinib and dasatinib for chronic myeloid leukaemia.
  • MERIT: NCRI trial of plasma exchange for myeloma (Chair).
  • Hovon/GMMG: Dutch/German trials of treatment for myeloma.
  • BALTI-2: Trial of treatment of head injury (Chair).
  • AVAST-M: Trial of adjuvant avastin for melanoma.
  • 3C study: Renal transplant trial.
  • CCCC trial: Anti-viral prophylaxis for prevention of CMV reactivation in immunocompetent patients in critical care

Trial Steering Committees

  • Myeloma XI trial

Publications

Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN. Hydroxycarbamide plus aspirin vs aspirin alone in patients with essential thrombocythaemia aged 40-59 years without high-risk features. Journal of Clinical Oncology 2018 (in press). 

Stevens SP, Main C, Bailey S, Pizer B, English M, Phillips R, Peet A, Avula S, Wilne S, Wheatley K, Kearns PR,  Wilson JS. The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review. Journal of Neuro-Oncology (2018) https://doi.org/10.1007/s11060-018-2901-x

Sackley CM, Smith CH, Rick CE, Brady MC, Ives N, Patel S, Woolley R, Dowling F, Patel R, Roberts H, Jowett S, Wheatley K, Kelly D, Sands G, Clarke CE; PD COMM Pilot Collaborative Group.Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot). Pilot and Feasibility Studies 2018; doi: 10.1186/s40814-017-0222-z. PMID: 29344405. 

Bate J, Baker S, Breuer J, Chisholm JC, Gray J, Hambleton S, Houlton A, Jit M, Lowis S, Makin G, O'Sullivan C, Patel SR, Phillips R, Ransinghe N, Ramsay ME, Skinner R, Wheatley K, Heath PT. PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Archives of Disease in Childhood. 2018; doi: 10.1136/archdischild-2017-314212. [Epub ahead of print]. PMID: 29730641. 

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen T, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. Journal of the National Cancer Institute 2018; 110: doi: 10.1093/jnci/djx133. PMID: 28922786.

Gains JE, Sebire NJ, Moroz V, Wheatley K, Gaze MN. Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue. Eur J Nucl Med Mol Imaging 2018; 45: 402-411. PMID: 2904339 

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature. Clin Cancer Res. 2017; 23: 6430-6440. PMID: 28765326. 

IvesNJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K. Adjuvant interferon‑α for the treatment of high-risk melanoma: an individual patient data meta-analysis. European Journal of Cancer 2017; 82: 171-83. PMID: 28692949. 

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G. Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). Pediatr Blood Cancer. 2017; 64: doi: 10.1002/pbc.26457. PMID: 28111876.

Marsden JR, Fox R, Boota NM, Cook M, Wheatley K, Billingham LJ, Steven NM. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study. Br J Dermatol. 2017; 176: 1148-54. PMID: 27714781. 

Turton AJ, Cunningham P, van Wijck F, Smartt H, Rogers CA, Sackley CM, Jowett S, Wolf SL, Wheatley K, van Vliet P. Home-based Reach-to-Grasp training for people after stroke is feasible: A pilot randomised controlled trial. Clin Rehabil. 2017; 31: 891-903. PMID: 27470470.

Ritchie J, Green D, Chrysochou T, Hegarty J, Handley K, Ives N, Wheatley K, Houston G, Wright J, Neyses L, Chalmers N, Mark P, Patel R, Moss J, Roditi G, Eadington D, Lukaschuk E, Cleland J, Kalra PA. Effect of renal artery revascularization upon cardiac structure and function in atherosclerotic renal artery stenosis: cardiac magnetic resonance sub-study of the ASTRAL trial. Nephrol Dial Transplant. 2017; 32: 1006-13. PMID: 27257278. 

Main C, Dandapani M, Pritchard M, Dodds R, Stevens SP, Thorp N, Taylor RE, Wheatley K, Pizer B, Morrall M, Phillips R, English M, Kearns PR, Wilne S, Wilson JS. The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review. Systematic Reviews 2016; 5: 124. PMID: 27460473. 

Main C, Stevens SP, Bailey S, Phillips R, Pizer B, Wheatley K, Kearns PR, English M, Wilne S, Wilson JS. The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. Systematic Reviews 2016; 5: 143. PMID: 27577246.

Wheatley K, Wilson JS, Gaunt P, Marsden JR. Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. Cancer Treatment Reviews 2016; 42: 73-81. PMID: 26563920. 

McIntosh E, Gray A, Daniels J, Gill S, Ives N, Jenkinson C, Mitchell R, Pall H, Patel S, Quinn N, Rick C, Wheatley K, Williams A. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial. Movement Disorders 2016; 31: 1173-82. PMID: 26846185.

Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, Wheatley K, Sheehan B, Sharp L, Stant KE, Fletcher-Smith J, Steel K, Barton GR, Irvine L, Peryer G. An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation. Health Technology Assessment 2016; 20: 1-138. PMID: 26927209. 

Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. April 2016. PMID: 27096326. 

Clarke CE, Patel S, Ives N, Rick CE, Dowling F, Woolley R, Wheatley K, Walker MF, Sackley CM. Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease: a randomized clinical trial. JAMA Neurology 2016; 73: 291-9. PMID: 26785394.

Main C, Wilson JS, Stevens SP, Houlton AE, English M, Kearns PR, Phillips B, Pizer B, Wilne S, Wheatley K. The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. Systematic Reviews 2015; 4: 168. PMID: 26589619. 

van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. European Journal of Cancer 2015; 51: 2453-64. PMID: 26271204. 

Jenkinson C, Clarke C, Gray R, Hewitson P, Ives N, Morley D, Rick C, Wheatley K, Williams A. Comparing results from long and short form versions of the Parkinson's disease questionnaire in a longitudinal study. Parkinsonism and Related Disorders 2015; 21: 1312-6. PMID: 26360237. 

Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, Wheatley K, Sheehan B, Sharp L, Stant KE, Fletcher-Smith J, Steel K, Wilde K, Irvine L, Peryer G. An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial. British Medical Journal 2015; 350 (epub: 5 February 2015, h468).

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer 2015; 51: 271-81. PMID: 25542058. 

Palin O, Herd C, Morrison KE, Jagielski AC, Wheatley K, Thomas GN, Clarke CE. Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. Parkinsonism and Related Disorders 2015; 21: 243-8. PMID: 25577023. 

Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Annals of Hematology 2015; 94: 361-73. PMID: 25284166.

 Moroz V, Wilson JS, Kearns P, Wheatley K. Comparison of anticipated and actual control group outcome in randomised trials in paediatric oncology provides evidence that non-randomised studies are biased in favour of the novel treatment. Trials 2014; 15: 481-90. PMID: 25490968. 

Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE on behalf of the UK PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384: 1196-1205.  PMID: 24928805. 

Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. European Journal of Cancer 2014; 50: 801-15. PMID: 24333097. 

Taylor RE, Howman AJ, Wheatley K, Brogden EE, Large B, Gibson MJ, Robson K, Mitra D, Saran F, Michalski A, Pizer BL. Hyperfractionated accelerated radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) medulloblastoma - A safety/feasibility study. Radiotherapy and Oncology2014; 111: 41-6. PMID: 24630538. 

Sackley CM, Smith CH, Rick C, Brady MC, Ives N, Patel R, Roberts H, Dowling F, Jowett S, Wheatley K, Patel S, Kelly D, Sands G, Clarke C. Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial. Trials 2014; 15: 213-19. PMID: 24908096.

 Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, Stowe R, Deane KH, Shah L, Sackley CM, Wheatley K, Ives N. Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev. June, 2014. PMID: 24936965.

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Bérard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. Journal of Clinical Oncology 2014; 32: 2440-8.  PMID: 24982464. 

Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Wheatley K, Ives N. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. September, 2013.  PMID: 24018704 

Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, Fisher D, Kearns P, Picton S, Saran F, Gibson M, Glaser A, Connolly DJ, Hargrave D. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy - Results of a United Kingdom phase II trial (CNS 2007 04). European Journal of Cancer 2013; 49: 3856-62.  PMID: 24011536 

Burnett A, Russell N, Hunter A, Milligan D, Knapper S, Wheatley K, Yin J, McMullin M, Ali S, Bowen D, Hills RK. Clofarabine doubles the response rate in older patients with acute myeloid leukaemia but does not improve survival. Blood 2013; 122: 1384-94.  PMID: 23838349 

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BES, Wheatley K, Milligan D. Optimisation of chemotherapy for younger patients with acute myeloid leukaemia: results of the MRC AML15 trial. Journal of Clinical Oncology 2013; 31: 3360-8.  PMID: 23940227 

Burnett AK, Goldstone A, Hills R, Milligan D, Prentice A, Yin J, Wheatley K, Hunter A, Russell NH. The curability of patients with AML who did not undergo transplantation in first remission. Journal of Clinical Oncology 2013; 31: 1293-301.  PMID: 23439754 

Turton AJ, Cunningham P, Heron E, van Wijck F, Sackley C, Rogers C, Wheatley K, Jowett S, Wolf SL, van Vliet P. Home-based reach-to-grasp training for people after stroke: study protocol for a feasibility randomised controlled trial. Trials 2013; 14: 109-118.  PMID: 23782653 

Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, Dezoysa J, Ives N, Clark WF, Quillen K, Winters JL, Wheatley K, Jayne D. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14; 73-79.  PMID: 23497590 

Gains JE, Stacey C, Rosenberg I, Mandeville HC, Chang YC, D'Souza D, Moroz V, Wheatley K, Gaze MN. Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma. Future Oncology 2013; 9: 439-49. PMID: 23469979. 

Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013; 27: 75-81.  PMID: 22964882 

Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF, Kell J, Wheatley K, Yin JAL, Hunter A, Milligan D, Russell NH. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 2013; 27: 1-9.  PMID: 23222369

Sackley CM, Burton CR, Herron-Marx S, Lett K, Mant J, Roalfe AK, Sharp LJ, Sheehan B, Stant KE, Walker MF, Watkins CL, Wheatley K, Williams J, Yao GL, Feltham MG. A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol. BMC Neurology 2012; 12: 52.  PMID: 22776066 

Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, Shah L, Sackley C, Deane KH, Wheatley K, Ives N. Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ 2012; 345: e5004.  PMID: 22867913 

Yin JA, O’Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial 2012. Blood 2012; 120: 2826-35.  PMID: 22875911 

Campbell P, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian J-J, Forsyth CJ, Harrison CN, Green AR. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120: 1409-11.  PMID: 22709688 

Burnett AK, Russell NH, Hills R, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukaemia. Journal of Clinical Oncology 2012; 30: 3924-31.  PMID: 22851554

Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, Milligan D. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology 2012; 158: 519-22.  PMID: 22639959

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. May, 2012.  PMID: 22592688

 Moroz V, Wilson J, Wheatley K. Comparison of anticipated and actual control group outcome in randomised trials in paediatric oncology provides evidence that non-randomised studies are biased in favour of the novel treatment. Trials 2011; 12 (Suppl 1): A108. 

Gibson BES, Webb DKH, Howman AJ, De Graaf SSN, Harrison CJ, Wheatley K. MRC AML 12: results of a randomised trial in children with acute myeloid leukaemia. British Journal of Haematology 2011; 155: 366-76.  PMID: 21902686 

Bate J, Chisholm J, Heath P, Breuer J, Skinner R, Manley S, Patel S, Wheatley K, Ramsay M, Kearns P, Hambleton S. PEPtalk: postexposure prophylaxis against varicella in children with cancer. Archives of Disease in Childhood 2011; 96: 841-5.  PMID: 21715391 

Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin MF, Cahalin P, Craig J, Bowen D, Russell N. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 2011; 25: 1122-7.

Clarke CE, Patel S, Ives N, Rick C, Wheatley K, Gray R. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Movement Disorders 2011; 26: 1187-93.  PMID: 21495068 

Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. American Journal of Hematology 2011; 86: 18-24. 

Ball AK, Howman A, Wheatley K, Burdon MA, Matthews T, Jacks AS, Lawden M, Sivaguru A, Furmston A, Howell S, Sharrack B, Davies MB, Sinclair AJ, Clarke CE. A randomised controlled trial of treatment for idiopathic intracranial hypertension. Journal of Neurology 2011; 258: 874-81.  PMID: 21161260 

Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH, Wheatley K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology 2011; 29: 369-77.  PMID: 21172891 

Hübel K, Weingart O, Naumann F, Bohlius J, Fresen MM, Engert A, Wheatley K. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leukemia and Lymphoma 2011; 52: 444-57.  PMID: 21323525 

Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, van Hilten JJ, Wheatley K, Gray R. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Movement Disorders. 2011; 26: 587-98.  PMID: 21370258

van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599-606. 

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews 2010: CD003188.  PMID: 20238320 

Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SS, van den Berg E, Burnett AK, Gibson BE. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Journal of Clinical Oncology 2010; 28: 2674-81.  PMID: 20439644 

Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurology 2010; 9: 581-91.  PMID: 20434403 

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010; 116: 354-65.  PMID: 20385793 

Burnett A, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin M-F, Duncombe A, Gibson B, Wheatley K. Attempts to optimise induction and consolidation treatment in AML: results of the MRC AML12 trial. Journal of Clinical Oncology 2010; 28: 586-95.  PMID: 20038732 

Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, Guy C, Gilkes A, Milligan DW, Goldstone AH, Prentice AG, Wheatley K, Linch DC, Gale RE. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010; 115: 948-56.  PMID: 19965647 

Wheatley K, Ives N, Kalra P, Moss J, Baigent C, Carr S, Chalmers N, Eadington D, Gray R, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal artery stenosis. New England Journal of Medicine 2009; 361: 1953-62.  PMID: 19907042 

Hills RK, Gray R, Wheatley K. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. Journal of Evidence-Based Medicine 2010; 2: 196-204.  PMID: 21349013